VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 801–900 of 1,000
Li, S., Weng, J., Xiao, C., Lu, J. N., Cao, W., Song, F., He, Z., Zhang, P., Zhu, Z., & Xu, J. (2023) · Cancer Reports · doi:10.1002/cnr2.1904 · Cited by 12
“28,29 Therefore, cuproptosis may play an important role in TME and immunotherapy in HCC.”
BackgroundInflammation-Associated Cytotoxic Agents in Tumorigenesis
Arnhold, J. (2023) · Cancers · doi:10.3390/cancers16010081 · Cited by 8
“…by the inhibition of the DC functions and maturation, by the infiltration of immunosuppressive cells (Treg, MDSC, and TAMs) into tumors, by reducing cytotoxic CD8 + T cell infiltration into tumors, and by the expression of the factors involved in the exhaustion of these cells [60–62].”
BackgroundSjöberg, E. (2024) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v129.10632 · Cited by 10
“In addition to the immunosuppressive effects of hypoxia, VEGF-signaling can also suppress immune functions (19–21) of importance for cancer patient survival (22).”
BackgroundLiu, X., Zhou, Q., Xu, Y., Chen, M., Zhao, J., & Wang, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21160 · Cited by 7
“Similarly, MEK inhibitors, a recent study in immunecompetent mice found that MEK inhibitors protected effector CD8 T-cells from death caused by chronic T cell receptor stimulation while sparing cytotoxic activity [32].”
BackgroundImmunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope
Brancewicz, J., Padzińska-Pruszyńska, I. B., Kubiak, M., & Kucharzewska, P. (2025) · Cells · doi:10.3390/cells14130995 · Cited by 7
“Preclinical data suggest that VEGF blockade enhances T-cell infiltration, potentially improving check-point inhibitor efficacy [151].”
Pro-Angiogenic Bioactive Molecules in Vascular Morphogenesis: Integrating Endothelial Cell Dynamics
Lungu, C. N., Gurău, G., & MEHEDINTI, M. C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100851 · Cited by 9
Merle, P., Blanc, J.-F., Malicot, K. L., Peron, J.-M., Bourgeois, V., Bouattour, M., Touchefeu, Y., Vitellius, C., Akouz, F. K., Heurgué, A., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00115-9 · Cited by 6
Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma
Nagai, H., Mukozu, T., Kobayashi, K., Nogami, A., Nagumo, H., Mohri, K., Watanabe, G., Amanuma, M., Yoshimine, N., Ogino, Y., et al. (2022) · Oncology · doi:10.1159/000527306 · Cited by 7
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
Kessler, E. R., Callihan, E., Hu, J., Eule, C. J., Srivastava, G., Kemme, D. J., Iruku, P., Rana, V., Moore, J., Schuster, S. R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0060 · Cited by 7
“Hypothyroidism 19 (42) 0 Hypophosphatemia 11 (24) 8 (18) Proteinuria 12 (27) 0 Anemia 8 (18) 1 (2) Hypokalemia 8 (18) 0 Increased blood creatinine 5 (11) 2 (4) Hypomagnesemia 5 (11) 1 (2) Increased alkaline phosphatase 4 (9) 1 (2) Hyperglycemia 2 (4) 2 (4) Hypocalcemia 2 (4) 1 (2)”
BackgroundManaging Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Barragán-Carrillo, R., Govindarajan, A., Rock, A. G., Sperandio, R. C., & Pal, S. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.005 · Cited by 6
Immunotherapy for mucosal melanoma
Du, Y., Bai, X. L., & Si, L. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000019 · Cited by 8
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma
Yang, S., Yang, X., Hou, Z., Zhu, L., Yao, Z., Zhang, Y., Chen, Y., Teng, J., Fang, C., Chen, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29215 · Cited by 10
Cheon, J., Jung, S., Kim, J. S., Kang, B., Kim, H., Chan, L. L., Becker, L., Gaillard, V. E., Chan, S. L., Kim, C., et al. (2024) · Liver International · doi:10.1111/liv.15935 · Cited by 8
Danzeng, A., Guo, L., Yang, Z., He, Z.-W., Zeng, C., Ciren, P., Lan, R.-H., Jiang, X., Wang, C., & Zhang, B. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.05.001 · Cited by 8
Yang, P., Luo, H., Zhao, L., Xiong, F., & Tang, C. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-394 · Cited by 6
“…T cells and myeloid-derived suppressor cells (13,14), recruitment of tumor-associated macrophages leading to T cell inactivation (15), up-regulation of PD-1 expression on T cells to induce T cell exhaustion (16), and direct inhibition of T cell proliferation and cytotoxic activity (17,18).”
Abdallah, M., Voland, R. P., DeCamp, M. M., Flíckinger, J. C., Pacioles, T. O., Jamil, M. O., Silbermins, D., Shenouda, M. N., Valsecchi, M. E., Bir, A., et al. (2024) · Cancers · doi:10.3390/cancers16244207 · Cited by 8
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies
Musnier, A., Corde, Y., Verdier, A., Cortès, M., Pallandre, J., Dumet, C., Bouard, A., KESKES, A., Omahdi, Z., Puard, V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1499810 · Cited by 7
“This accumulation is thought to be insurmountable for anti-PD-1 antibodies alone to restore T cells activation (6 – 8).”
Kido, Y., Ando, T., Iga, T., Ema, M., Kubota, Y., & Tai-Nagara, I. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.11.003 · Cited by 6
Epithelial Stem Cells: Making, Shaping and Breaking the Niche
Ferraces-Riegas, P., Galbraith, A. C., & Doupé, D. P. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_686 · Cited by 6
Ueda, S., Hori, S., Hori, A., Makitani, K., Wan, K., & Sonomura, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s380439 · Cited by 6
“Bevacizumab is thought to reduce myeloid derived suppressor cells and regulatory T cells, thereby releasing immunosuppression of the tumor microenvironment.(48,49) Therefore, TACE combined with intra-arterial infusion of bevacizumab may suppress hypoxia-induced VEGF secretion, inhibit invasion and metastasis, and norm…”
BackgroundInteraction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages
Liu, X., Li, Z., Sun, J., Zhang, Z., & Li, W. (2023) · BMC Cancer · doi:10.1186/s12885-023-10733-5 · Cited by 9
“In addition, anti-VEGF antibody promotes the expression intensity of immune checkpoints such as PD-1, CTLA-4 and TIM-3 on CD8+ T cells [12].”
BackgroundSicard, G., Protzenko, D., Giacometti, S., Barlési, F., Ciccolini, J., & Fanciullino, R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02350-7 · Cited by 6
“Additionally, anti-VEGF was found to decrease Tregs in mice bearing tumor [35, 36].”
BackgroundSun, J., Adenis, A., Enzinger, P. C., Shah, M. A., Kato, K., Bennouna, J., Doi, T., Hawk, N. N., Yu, L., Shah, S., et al. (2024) · Future Oncology · doi:10.2217/fon-2022-1148 · Cited by 8
Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation
Yakoub, A. M., Schulz, R., Seiffert, M., & Sadek, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-28901-0 · Cited by 6
Lee, K. S., Yun, S., Lee, K., Moon, S., & Choe, G. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.03.013 · Cited by 7
Treating Colorectal Cancer with Immunotherapy: Implications for Single Versus Combination Therapy
Karki, S., Umar, S., & Kasi, A. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00459-y · Cited by 8
Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’
Sobottka, B., Lorch, A., Siliņa, K., van den Broek, M. F., & Moch, H. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000864 · Cited by 6
Sho, T., Morikawa, K., Kubo, A., Tokuchi, Y., Kitagataya, T., Yamada, R., Shigesawa, T., Kimura, M., Nakai, M., Suda, G., et al. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i12.2076 · Cited by 8
Inhibiting VEGF in cancer immunotherapy
Shibata, M., Kono, K., & Takenoshita, S. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.12.003 · Cited by 8
Immunotherapy for hepatocellular cancer: beginning and future perspectives
Kazantseva, M. A., Breder, V. V., & Лактионов, К. К. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-10-15-21 · Cited by 6
The multifaceted modulation of mitochondrial metabolism in tumorigenesis
Keerthiga, R., Xie, Y., Pei, D., & Fu, A. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101977 · Cited by 8
Liang, M.-Z., Huang, X.-F., Zhu, J., Bao, J., Chen, C., Wang, X., Lou, Y.-W., Pan, Y.-T., & Dai, Y. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108507 · Cited by 6
Immunotherapy in central nervous system tumors
Huang, Y., Liu, Y., Zeng, H., Yang, J., Li, Z., Xu, J., Jin, L., Liu, X., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002993 · Cited by 6
“In the VEGF-A knockout tumor model, the levels of these depletion markers on tumor-infiltrating CD8 + T cells were significantly reduced [ 134 ] .”
Pan, J., Chen, S., Jin, L., Chen, K., Ye, Z., & Li, B. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189544 · Cited by 8
Gao, T. A., Shih, R. M., Clubb, J. D., Hung, S.-H., Singh, T., James‐Allan, L. B., DiBernardo, G., Shafer, A. M., Bouren, A., Ceja, M. A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw9286 · Cited by 8
Chen, D., Wu, R., Liu, Z., Wei, Y., & Kuang, D. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004035 · Cited by 6
“[110] Targeting VEGF offers the dual benefit of vascular normalization and immune reactivation.”
Ma, Y., Yu, J., Ma, X., Li, Q., Su, Q., & Cao, B. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13961 · Cited by 6
“44,45 45 Given that the overall response rate (ORR) of immunotherapy is only about 20%, neither immunotherapy nor chemotherapy monotherapy has achieved satisfactory treatment outcomes to date.”
BackgroundEgerer, M., Schuch, K., Schöler, D., Artusa, F., Puengel, T., Holtmann, T. M., Loosen, S. H., Demir, M., Wree, A., Luedde, T., et al. (2024) · Cancers · doi:10.3390/cancers16213651 · Cited by 5
“Anti-VEGF therapies mitigate VEGF-induced immunosuppression in both the tumor and its surrounding microenvironment [7,8] and might amplify anti-PD-L1 efficiency due to the reversion of VEGF-mediated immunosuppression and promotion of T-cell infiltration in tumors [9–11].”
BackgroundPark, S., Park, K., Kim, C., & Rhie, S. J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104630 · Cited by 6
Levallet, G., Créveuil, C., Léger-Vigot, A., Brosseau, S., Danel, C. J., Scherpereel, A., Lantuéjoul, S., Mazières, J., Greillier, L., Audigier-Valette, C., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102520 · Cited by 6
Noninvasive Identification of Immune-Related Biomarkers in Hepatocellular Carcinoma
Li, L., Zhao, H., Chen, B., Huang, K., Hao, Z., Fan, Z., Sun, G., Wu, J., Li, N., Ye, Q., et al. (2019) · Journal of Oncology · doi:10.1155/2019/2531932 · Cited by 5
“In addition, tumor can produce VEGFA, which increases expression of inhibitory immune checkpoints mediating Tcell exhaustion on intratumoral CD8+ Tcells [28].”
BackgroundMohsenzadegan, M., Nowroozi, M. R., Fotovvat, A., Baghshahi, P. B., Bokaie, S., Inanloo, S. H., & Sharifi, L. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13197 · Cited by 5
Qiu, L., Liu, C., & Li, H. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001546 · Cited by 5
Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation
Bai, W., Tang, X., Xiao, T., Qiao, Y., Tian, X., Zhu, B., Chen, J., Chen, C., Li, Y., Lin, X., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200813 · Cited by 6
Li, G., Li, Z., Shen, J., Ma, X., Zheng, S., Zheng, Y., Cao, K., & Dong, N. (2024) · Gene · doi:10.1016/j.gene.2024.148796 · Cited by 6
Immune therapy in colorectal cancer
Lapeyre-Prost, A., Terme, M., Pernot, S., Marcheteau, E., Pointet, A., Voron, T., Tartour, É., & Taïeb, J. (2017) · Colorectal Cancer · doi:10.2217/crc-2017-0002 · Cited by 6
Self-citationNormalizing the Tumor Microenvironment for Radiosensitization
Martin, J. D., & Jain, R. K. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_12 · Cited by 5
Tozuka, T., Yanagitani, N., Sakamoto, H., Yoshida, H., Amino, Y., Uematsu, S., Yoshizawa, T., Hasegawa, T., Ariyasu, R., Uchibori, K., et al. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100249 · Cited by 6
Impact of General Factors on Glioma Immunotherapy
Huang, Q., Wang, D., Yao, G., & Wang, H. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.1.3 · Cited by 6
Corte, A. D., Rimini, M., Steidler, S., Palumbo, D., Ratti, F., Aldrighetti, L. A., Cascinu, S., Gardini, A. C., & COBELLI, F. D. (2022) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-022-03327-4 · Cited by 7
Li, F., Lu, H., Zhao, D. F., & Shen, Z. (2023) · Journal of International Medical Research · doi:10.1177/03000605231174973 · Cited by 5
“VEGFR2 is involved in the depletion of T cells through binding with CD8þ T cells.(45) In this current case, it is likely that the effect of VEGF and VEGFR on T cells was improved by the addition of TKI drugs, thus enhancing the antitumour effect of ICIs.”
BackgroundNoé, G., Bellesœur, A., Golmard, L., Thomas‐Schoemann, A., Boudou, P., Meyo, M. T., Puszkiel, A., Arrondeau, J., Alexandre, J., Goldwasser, F., et al. (2019) · Cancers · doi:10.3390/cancers11060762 · Cited by 6
“Different studies showed that VEGF-A enhances the expression level of PD-1 on lymphocytes [28,29].”
BackgroundFujiwara, Y., Yamaguchi, T., & Nakane, M. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5456-20 · Cited by 6
“In addition, these agents are also reported to inhibit the immunosuppressive effect in the tumor microenvironment, suggesting the possibility of having synergetic effects when used with immune checkpoint inhibitors (2, 3).”
BackgroundSugiyama, G., Nio, K., Okada, H., Kida, A., Sako, K., Iwata, Y., Takayama, H., Kawakami, Y., Chiba, T., Nagai, K., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100778 · Cited by 4
“Because VEGF signaling contributes to CD8-positive T cell exhaustion by promoting the expression of checkpoint molecules such as PD1 and TIGIT, 22,23 VEGFR2 inhibition may be a promising therapeutic target for enhancing antitumor immune activity.”
Huang, Z., Chen, T., Li, W., Qiu, J., Liu, S., Wu, Z., Li, B., Yuan, Y., & He, W. A. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01415-y · Cited by 5
Liu, H., Hao, Q., Wang, X., Cheng, M., Qiu, F., & Zhou, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1502945 · Cited by 5
Jia, H., Nowocin, A. K., Burns, C. J., & Wadhwa, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136280 · Cited by 5
Dalbeni, A., Cattazzo, F., Vicardi, M., Franceschini, E., Campani, C., Cabibbo, G., Vivaldi, C., Palloni, A., Pressiani, T., Iavarone, M. A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-25752-4 · Cited by 4
Cao, Y. (2026) · Immunity & Inflammation · doi:10.1007/s44466-025-00021-1 · Cited by 6
Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies
Huang, K., & Chen, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073064 · Cited by 6
Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment
Wu, Y., Su, Y., Wei, Y., Shui, M., Li, W., Yang, L., & Luo, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114915 · Cited by 6
Zhou, N. Q., Lei, C.-F., Tan, S., Huang, Q., Zhang, S., Liang, Z., & Gou, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190967 · Cited by 5
“In addition to the known antiangiogenic effects, the inhibition of vascular endothelial growth factor (VEGF) such as lenvatinib has immunomodulatory effects (Voron et al., 2015).”
BackgroundTeisseire, M., Giuliano, S., & Pagès, G. (2024) · Biomedicines · doi:10.3390/biomedicines12020385 · Cited by 5
“Consequently, this dual impact decreases the efficacy of anti-tumour immunotherapies.”
BackgroundSuwannaphoom, K., Soontornsit, S., Wiwatwarayos, K., Seneetuntigul, P., & Julimasart, P. (2024) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2024.152294 · Cited by 5
Dong, C., Hu, C., Jiang, Y., Hui, K., & Jiang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368059 · Cited by 4
“VEGF also inhibits dendritic cell maturation and activation, limiting antigen presentation (15, 16).”
BackgroundMultifaceted roles of PD‐1 in tumorigenesis: From immune checkpoint to tumor cell‐intrinsic function
Chen, H., Wei, J., Zhu, Z., & Hou, Y. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23740 · Cited by 4
ADAM10 modulates the efficacy of T‐cell‐mediated therapy in solid tumors
Abdalla, A. M. E., Miao, Y., Ming, N., & Ouyang, C. (2024) · Immunology and Cell Biology · doi:10.1111/imcb.12826 · Cited by 5
Somsuan, K., Rongjumnong, A., Morchang, A., Hankittichai, P., Ngoenkam, J., Makeudom, A., Lirdprapamongkol, K., Krisanaprakornkit, S., Pongcharoen, S., Svasti, J., et al. (2025) · Biomedical Reports · doi:10.3892/br.2025.1955 · Cited by 6
“VEGF can promote an immunosup‑ pressive environment by inhibiting the activity of immune cells such as cytotoxic T cells and dendritic cells (41,42).”
Yu, Y., Di, Y., Li, P., Nie, Q.-Z., Chen, X., Wang, Y., & Ren, K. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110512 · Cited by 4
Park, B., Heo, S., Lee, Y. J., Seo, M.-K., Hong, J., Shin, E., Jung, I., & Kim, S. (2022) · iScience · doi:10.1016/j.isci.2022.104467 · Cited by 5
Wu, Y., Zhang, X., Li, L., Yang, W., Yan, Z., Gu, C., Zhang, Z., Zhou, J., Liu, L., Ye, M., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s375643 · Cited by 4
“Angiogenic factors like VEGF could create an immunosuppressive environment by the release of inhibitory cytokines and the recruitment of immunosuppressive cell types.(26) Thus, the combined targeting of angiogenesis and immune checkpoints is deemed to facilitate a more robust immune response to therapy.”
Omoboyede, V., Ibrahim, O., Umar, H. I., Oke, G. A., Onile, O. S., & Chukwuemeka, P. O. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00498-6 · Cited by 9
Pan, D., Liu, H., Qu, P., Chen, X., Ma, X., Wang, Y., Qin, X., & Han, Z. (2024) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-5159 · Cited by 4
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 7
Rôle du VEGF dans l’épuisement des lymphocytes T intratumoraux
Voron, T., Tartour, É., Taïeb, J., & Terme, M. (2015) · médecine/sciences · doi:10.1051/medsci/20153105004 · Cited by 6
Self-citationCreasy, C. A., Forget, M., Singh, G., Tapia, C., Xu, M., Stephen, B., Sabir, S. H., Meric‐Bernstam, F., Haymaker, C., Bernatchez, C., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201948217 · Cited by 4
Current state and perspectives of checkpoint inhibitors in ovarian cancer treatment
Bartl, T., Paspalj, V., Polterauer, S., & Grimm, C. (2020) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-020-00579-z · Cited by 4
Sweet-Cordero, A., Marini, K. D., Champion, E. C., Lee, A. G., Young, I., Leung, S. G., Mathey‐Andrews, N., Jacks, T., Jackson, P. K., & Cochran, J. R. (2024) · Research Square · doi:10.21203/rs.3.rs-4046823/v1 · Cited by 6
“VEGF has also been shown to directly in�uence T cell response by increasing the expression of immunosuppressive checkpoints 43,44 .”
BackgroundCheng, C. C. Y., Cheung, M. F., Lee, A. Y., Wu, Q., Chow, S. H.-C., Ang, J. Y. J., Riquelme Medina, I., Lo, G., Wu, H., Yang, W., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09154-w · Cited by 3
“6h) 89 – 91 .”
He, M., Xie, W., Yuan, Z., Chen, J., Wang, J., Fu, Y., Hu, Z., Meng, Q., Gao, W., Hu, D., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35341 · Cited by 3
“14,15 This mechanism potentially enhances the efficacy of immune checkpoint inhibitors (ICIs) by promoting T-cell infiltration into tumors.”
Von Hippel–Lindau/Hypoxia Inducible Factor Axis in Glioblastoma
Flores, I., Salazar, A., de la Cruz, V. P., Mena-Guerrero, T., Cossio, J. Á. N., Figueroa, R., Cancino-Diaz, M. E., & Pineda, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209979 · Cited by 3
“This immunosuppressive effect could be reversed through pharmacological inhibition of tyrosine kinase inhibitor (TKI) that blocks vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1, VEGFR2, and VEGFR3) in tumor models [107].”
Liu, Y., Xiao, L., Nie, X., Lyu, J., Tang, C., Li, L., Zhang, X., Li, T., Huang, J., & Zhang, S. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2610526 · Cited by 3
IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy
Chen, D., Wu, Z., Zhao, X., Bhatt, R. S., Yang, Y., Zhu, W., Tang, H., Wang, K., Guo, C., Liu, D., et al. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag002 · Cited by 5
Nanomedicine-Mediated Immunotherapy for Cancer Treatment
Hou, W., Song, W., Zhang, R., Lomova, M. V., Sadovnikov, А. V., & Song, Y. J. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c02061 · Cited by 4
Lucantonio, L., Schiano, L., Sozio, F., Kosta, A., Peruzzi, G., Molfetta, R., Pietropaolo, G., Laffranchi, M., Campese, A. F., Bernardini, G., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2674362 · Cited by 3
Shibutani, T., Goto, R., Miyazaki, I., Hashimoto, A., Suzuki, T., Ishida, K., Haruma, T., Osada, T., Harada, T., Fujita, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35985-w · Cited by 3
“It has been reported to inhibit the M-CSF/CSF1R signaling pathway and M-CSF-dependent macrophage differentiation into osteoclasts 10,11,29 .”
Matsudo, K., Takada, K., Hashinokuchi, A., Nagano, T., Kinoshita, F., Akamine, T., Kohno, M., Takenaka, T., Shimokawa, M., Oda, Y., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16806-4 · Cited by 5
“21,22 Furthermore, reduced oxygen supply to the tumor due to increased immature blood vessels, resulting from excessive VEGF production, is thought to promote tumor progression by inducing an immunosuppressive microenvironment.”
Balmaceda, N. B., & Kim, S. S. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01624-4 · Cited by 3
“VEGF promotes upregulation of PD-1, CTLA-4 and TIM3 on TILs, resulting in T cell dysfunction [83].”
Evolving Frontline Treatment Landscape for Advanced or Metastatic Renal Cell Carcinoma
Jain, R., & Lara, P. N. (2020) · Kidney Cancer · doi:10.3233/kca-200088 · Cited by 3
Immunotherapy in hepatocellular cancer
Fountzilas, C. K., Evans, R., Alaklabi, S., & Iyer, R. V. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.12.002 · Cited by 4
Immune Response Role of Angiogenesis Inhibitors
Nemunaitis, J. J., Devanaboyina, M., Ngo, N. T., Albalawy, R., Filipiak, L., Staats, H., Stanbery, L., Hamouda, D., & Nemunaitis, J. J. (2021) · Clinical Oncology and Research · doi:10.31487/j.cor.2021.02.01 · Cited by 2
“The VEGF blockade can lead to upregulation of anti-tumor T cell response without inhibition of the pathway, as blockade of VEGF also results in increased IFN- levels [74].”
BackgroundComparing immunotherapies to other frequently used treatments of gastric cancer
Basile, D., Simionato, F., Calvetti, L., Cappetta, A., Pesavento, A., Mongillo, M., Roviello, G., Rosati, G., Rossi, G., & Aprile, G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938546 · Cited by 3
Xiao, G., Gao, X., Li, L., Liu, C., Liu, Z., Peng, H., Xia, X., Yi, X., & Zhou, R. (2021) · Journal of Oncology · doi:10.1155/2021/3766685 · Cited by 3
“In addition, tumor cells produce VEGF-A, which can increase the expression level of PD-1, CTLA-4, and TIM-3 in CD8+ T cells, thereby inducing T-cell exhaustion [92].”
BackgroundResistance to antiangiogenic treatments: A review
Koltai, T., Reshkin, S. J., & Cardone, R. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00014-7 · Cited by 4
Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
Tsao, S. Y. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00107 · Cited by 4
“Recently, several TCM herbs have been discovered to have an action against VEGFs [18, 23].”
BackgroundInfluentialLei, Y., Li, L., Cheng, S.-Y., Shao, Q., Ding, C., Zuo, R., Chen, W., Liao, Q., & Liu, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1072480 · Cited by 2
Chen, D., Wang, Y., Chen, X., Kang, M., & Zhu, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-40030-x · Cited by 3
García‐Irigoyen, A., Guzmán‐Bucio, S., Aranda‐Audelo, M., Moore, Z. R., Trinidad‐Bibiano, H., & Elisa, V. M. M. (2024) · Health Science Reports · doi:10.1002/hsr2.1855 · Cited by 2
“6,7 The role of seric and cutaneous CD8+ TL are poorly understood in KS, and no studies have evaluated the role of cutaneous CD8+ TL and CD4:CD8 cutaneous ratio in skin biopsies.”
BackgroundTumor-specific Peptide Probes and the Applications in Bioimaging
Wang, B., Cai, X., & Xiao, J. (2024) · 化学学报 · doi:10.6023/a23100448 · Cited by 3
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma
Proulx-Rocray, F., & Soulières, D. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2339906 · Cited by 5
“…this proangiogenic pathway was associated with increased expression of inhibitory receptors on T-cells (PD-1, CTLA-4, TIM-3 and LAG-3), reduced cytotoxic T-cells activity and proliferation, reduced NK cells cytotoxicity, and increased recruitment of regulatory T-cells (Tregs) into tumors [55–58].”
Background
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.